Drug Profile
Research programme: amyloid precursor protein secretase inhibitors - Merck & Co
Alternative Names: BACE programme - Merck & Co; SCH 697466; SCH 723909; SCH 741216; SCH 747123; SCH-1375975; SCH-745966; β-secretase-1 inhibitors - Merck & Co; γ-secretase inhibitors - Merck & CoLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Class Amides; Hydantoins; Small molecules; Urea compounds
- Mechanism of Action Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 13 Nov 2010 Pharmacodynamics data from animal studies in Alzheimer's disease presented at the 40th Annual Meeting of the Society for Neuroscience (SFN-2010)
- 20 Aug 2009 Pharmacodynamics data from in vitro and preclinical studies in Alzheimer's disease presented at the 238th American Chemical Society National Meeting (238th-ACS-2009) ,,,,,,